Return to the Table of Contents

Jefferson Scientists Use Gene Therapy to Restore Function of Damaged Human Heart Cells in Laboratory

Research targets enzyme elevated in human heart failure

Researchers at Jefferson Medical College (JMC) of Thomas Jefferson University in Philadelphia, PA, and at Duke University Medical Center in Durham, NC, have used gene therapy to help damaged heart cells regain strength and beat normally again in the laboratory. The work takes the scientists one step closer to eventual clinical trials in humans.

Walter Koch, PhD, Director of the Center for Translational Medicine of the Department of Medicine at JMC, and his colleagues at Duke used a virus to carry a gene into the heart cells of individuals who had suffered from congestive heart failure. The gene introduced into these heart cells blocks the activity of an enzyme that is increased in failing human hearts and which contributes to the loss of the heart’s contractile strength during the development of heart failure. When the activity of this enzyme was blocked by the gene therapy, the heart cells were able to contract at normal strength and their overall performance was improved.

These findings of Dr. Koch and his colleagues recently appeared in Circulation, a journal of the American Heart Association.

Activity of Troublesome Enzyme Inhibited
According to Dr. Koch, who is W.W. Smith Professor of Medicine at JMC, researchers have known for some time that the beta-adrenergic receptor system fails to work properly in individuals with congestive heart failure. Such receptors “drive the heart – both by rate and force of contraction,” he says.

The researchers’ target has been the beta-adrenergic kinase (ßARK1), an enzyme that is elevated in human heart failure. One of its functions is to turn off beta-adrenergic receptors. “In heart failure, beta adrenergic receptor density is decreased, ßARK is increased and both together cause dysfunctional beta-receptor signaling,” Dr. Koch says. “A failing heart then has little capacity to respond to exercise or stress because there are fewer receptors and the remaining receptors are more or less turned off. “We have thought that inhibiting ßARK activity could increase signaling and increase function.”

In the laboratory dish, the researchers infected heart cells from patients who underwent cardiac transplantation due to end-stage heart failure with a common cold virus that had been rendered non-infectious. The scientists utilized this virus to transport both ßARKct – an inhibitor peptide (compound of aminio acids) that can block ßARK – and a therapeutic, so-called “reporter gene” protein, which glows green, to the failing heart cells. The reporter gene provided a signal to the scientists that the inhibitor was indeed present in the heart cells. The scientists were then able to use a video camera to actually measure how strong the individual heart cells were beating.

“We put the ßARKct into the cells, and failing human hearts become more like normal hearts, based on their ability to contract, and other functional properties of these cells were also improved,” Dr. Koch says. “This is the first work in actual human hearts to show efficacy of ßARKct as a potential therapy, and, more importantly, it proves that the enzyme ßARK1 is a target for heart failure treatment.”

Confirms Findings of Research Done on Animal Hearts
“This study is the last proof of concept,” he adds, noting that years of previous work in various animal models enabled the research team to reach this point. “Now we are dealing with human cells from failing human hearts,” he says, noting that essentially these studies in human heart cells “confirm all we have done.”

Congestive heart failure affects nearly five million Americans, many of whom have poor long-term prognoses, despite recent therapeutic advances. Dr. Koch hopes that such studies will move gene therapy forward as a viable option for heart failure patients. He notes that pre-clinical studies in “clinically relevant” large animal models are progressing and should eventually lead to human trials using the ßARKct gene.